Drug Profile
KF 070
Alternative Names: KF-070Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Asthma in China
- 14 Sep 2017 KF 070 is available for licensing as of 14 Sep 2017. http://www.akesobio.com/index.php?siteid=2
- 14 Sep 2017 Early research in Asthma in China (unspecified route) (Akeso Biopharma pipeline, September 2017)